July 13, 2011
RXi Expands Patents
By Brandon Butler
RXi Pharmaceuticals of Worcester is expanding the patent protection of its newly acquired drug.
RXi received additional patents to cover the worldwide rights to use NeuVax, a breast cancer therapy drug that was developed by Apthera. RXi purchased Apthera in April.
The company recently reported positive results from its phase-II clinical trial of NeuVax and expects to undertake a phase III clinical trial next year.
The patents were licensed from the Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
WBJ Web Partners
Most Recent
Most Recent
0 Comments